To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Zoledronic acid has no continued benefit beyond 6 years for osteoporosis

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
December 2015

Zoledronic acid has no continued benefit beyond 6 years for osteoporosis

Vol: 4| Issue: 12| Number:58| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)

J Bone Miner Res. 2015 May;30(5):934-44.

Contributing Authors:
DM Black IR Reid JA Cauley F Cosman PC Leung P Lakatos K Lippuner SR Cummings TF Hue A Mukhopadhyay M Tan RP Aftring R Eastell

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

One hundred and ninety patients were randomized to receive either continued zolderonic acid (ZOL) treatment or were switched to a placebo after six years of ZOL treatment for osteoporosis. Patients received treatment for an additional 3 years to determine continued efficacy and safety of ZOL. Results found that there was no significant benefit to continued ZOL treatment. Additionally, there was a ...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue